Industry News
510k clearance for Diasorin Simplexa COVID-19, Flu A/B, and RSV kit
The kit as broad coverage for influenza strains, emerging SARS-CoV-2 variants, and detection of both RSV subgroups A and B
News & Articles
25
Selected Filters:
Product News
Diasorin launches the Simplexa C. auris Direct assay on the LIASON MDX instrument in all countries accepting the CE mark
The assay is designed to improve infection control in healthcare settings through the rapid identification of patients suspected of Candida auris colonization
Product News
DiaSorin releases assay for rapid identification of SARS-CoV-2 variants
The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction
Product News
DiaSorin launches LIAISON SARS-CoV-2 TrimericS IgG test for determination of IgG antibodies
The test could be used to assess antibody response against the native spike protein of SARS-CoV-2 following COVID-19 vaccination
Industry News
DiaSorin's Simplexa COVID-19 direct molecular test CE marked for saliva specimens
The Direct assay is validated on a wide range of specimen types, and can be run in parallel with the Simplexa Flu A/B & RSV Direct Gen II assay
Industry News
DiaSorin partners with MeMed to develop and commercialize diagnostics solution
Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections
Product News
Improving Detection and Treatment of Whooping Cough
DiaSorin Molecular receives FDA clearance for Bordetella test
Product News
DiaSorin Molecular Secures FDA Clearance for Group B Strep Assay
Simplexa™ GBS Direct molecular assay enables in vitro detection of Group B Streptococcus
Product News
DiaSorin Launches the two Fastest Molecular Diagnostic Tests in the World to Detect Fulminant Leukemias
Early identification of the disease will allow specific and extremely effective therapies for the treatment of patients
